NCT05223088已完成2 期
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer: a Single-arm, Prospective, Multicenter Trial (TAOS-3B-Trial)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Total/moderate tumor regression rate under pathology
研究概览
简要总结
To evaluate the clinical efficacy and safety of Tislelizumab combined with apatinib mesylate, oxaliplatin plus S1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 18-70 years of age
- •Histologically confirmed gastric adenocarcinoma was diagnosed in patients with locally advanced gastric cancer with tumor volume >5cm Borrmann III, Borrmann IV and BulkyN according to AJCC Version 8
- •measurable lesions at least should be detected by CT/MRI examination in accordance with the RECIST1.
- •ECOG（Eastern Cooperative Oncology Group）PS（Performance Status）:0-1 scores;
- •No previous surgical treatment, anti-tumor chemoradiotherapy/immunotherapy was performed
- •Preoperative endoscopic examination confirmed no positive peritoneal implantation metastasis and exfoliated cells
- •the expected survival time is more than 6 months
- •the main organ function is normal, which should meet the following criteria:
- •ANC≥1.5×109/L
- •PLT≥100×109/L
- •TBIL≤1.5 normal upper limit ULN ；or TBIL>ULN but BIL≤ULN
- •ALT and AST≤2.5 ULN（ALT or AST ≤5×ULN was allowed in patients with liver metastasis）
- •Cr≤1.5 ULN，CCR（creatinine clearance rate）≥60ml/min(Cockcroft-Gault formula)
- •Good coagulation function, defined as international standardized ratio (INR) or prothrombin time (PT) ≤1.5 ULN
- •Normal thyroid function, defined as thyroid stimulating hormone (TSH) within the normal range.If the baseline TSH is outside the normal range, subjects with total T3 (or FT3) and FT4 within the normal range may be enrolled;
- •The myocardial enzyme profile is within the normal range (if the investigator comprehensively determines that the simple laboratory abnormality is not clinically significant, it is allowed to be included in the group
- •For women of reproductive age, a urine or serum pregnancy test with negative results should be performed within 3 days prior to receiving the first study drug administration (day 1 of cycle 1).If a urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is requested.Women of childbearing age were defined as at least 1 year after menopause or having undergone surgical sterilization or hysterectomy;。
- •If there is a risk of conception, all subjects (both men and women) are required to use a contraceptive with an annual failure rate of less than 1% throughout the treatment period up to 120 days after the last study drug (or 180 days after the last chemotherapeutic drug)
- •participants is willing to participate in this study, sign the informed consent, have good compliance, cooperate with follow-up.
排除标准
- •Diagnosis of malignant diseases other than gastric cancer within 5 years prior to first administration (excluding radical basal cell carcinoma of the skin, squamous carcinoma of the skin, and/or radical resectable carcinoma in situ);
- •Significant clinical bleeding symptoms or clear bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer or vasculitis, etc. occurred within 3 months before enrollment. If fecal occult blood was positive at baseline, reexamination could be performed; if it was still positive after reexamination, gastroscopy was required
- •Prior treatment: anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or drugs that target another stimulating or co-inhibiting T-cell receptor (e.g., CTLA-4, OX-40, CD137);
- •A history of immunodeficiency, including HIV testing positive.
- •Is currently participating in an interventional clinical study or has been treated with another study drug or study device in the 4 weeks prior to initial dosing.
- •Patients who had a history of cardiovascular and cerebrovascular diseases and were still taking thrombolytic drugs or anticoagulants orally.
- •HER2 positive is known;
- •Patients with previous gastrointestinal perforation, abdominal abscess or recent intestinal obstruction (within 3 months) or imaging or clinical symptoms suggesting intestinal obstruction;
研究组 & 干预措施
Tislelizumab combined with apatinib and oxaliplatin plus S1
Experimental
Neoadjuvant immunotherapy, PD-1, plus apatinib and oxaliplatin plus S1 will be applied to patients with Borrmann IV、large Borrmann III type and Bulky N positive advanced gastric cancer before surgery.
干预措施: Tislelizumab (Drug)
Tislelizumab combined with apatinib and oxaliplatin plus S1
Experimental
Neoadjuvant immunotherapy, PD-1, plus apatinib and oxaliplatin plus S1 will be applied to patients with Borrmann IV、large Borrmann III type and Bulky N positive advanced gastric cancer before surgery.
干预措施: Apatinib Mesylate (Drug)
Tislelizumab combined with apatinib and oxaliplatin plus S1
Experimental
Neoadjuvant immunotherapy, PD-1, plus apatinib and oxaliplatin plus S1 will be applied to patients with Borrmann IV、large Borrmann III type and Bulky N positive advanced gastric cancer before surgery.
干预措施: oxaliplatin (Drug)
Tislelizumab combined with apatinib and oxaliplatin plus S1
Experimental
Neoadjuvant immunotherapy, PD-1, plus apatinib and oxaliplatin plus S1 will be applied to patients with Borrmann IV、large Borrmann III type and Bulky N positive advanced gastric cancer before surgery.
干预措施: Tegafur (Drug)
结局指标
主要结局
Total/moderate tumor regression rate under pathology
时间窗: 4 weeks after surgery
Primary tumor or lymph node surgery specimen pathological examination without residual tumor cell
次要结局
- Objective Response Rate (ORR)(At the end of Cycle 3 (each cycle is 21 days))
- Overall survival (OS)(every 3 months (up to 24 months) ])
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric CancerImmunotherapy Gastrict CancerNCT05699655Fujian Cancer Hospital130
尚未招募
2 期
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric JunctionImmunotherapy Gastroesophageal JunctionNCT06396585Fujian Cancer Hospital28
已完成
2 期
First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GCAdvanced Gastric AdenocarcinomaNCT06238752Renmin Hospital of Wuhan University33
终止
3 期
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung CancerNon-small Cell Lung CancerNSCLCNCT04746924BeiGene669
已完成
不适用
Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast CancerBreast Cancer MetastaticNCT05609903Fondazione Policlinico Universitario Agostino Gemelli IRCCS52